Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:13 AM
Ignite Modification Date:
2025-12-25 @ 12:13 AM
NCT ID:
NCT05746858
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of DLBCL and RR-DLBCL;
* Age\>18 years;
* Eligibility for first-line and/or salvage chemo-immunotherapies as above specified;
* Measurable and/or evaluable disease (at least one bi-dimensionally measurable lesion on imaging scan defined as \>1.5 cm in its longest dimension);
* No concomitant active cancers or others life-threatening conditions that can compromise chemotherapy treatment;
* Available FFPE and fresh tumor tissue (excisional biopsy, Tru-cut microhistology);
* Informed consent to treatment and use of biologic materials for studies related to the present proposal.
Exclusion Criteria:
* Diagnosis of follicular lymphoma grade 3b, lymphoblastic lymphoma, Burkitt lymphoma or primary mediastinal lymphoma;
* Age ≤ 18 years;
* Ineligible for first-line and/or salvage chemo-immunotherapies;
* No measurable and/or evaluable disease;
* Patients with concomitant active solid tumors or others clinical conditions that can compromise chemotherapy treatment or negatively influence the prognosis;
* Known history of HIV seropositive status. HIV testing will be performed at screening
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05746858
Study Brief:
Protocol Section:
NCT05746858